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esponsibility of InstAbstract Nanocrystals are pure drug crystals with sizes in the nanometer range. Due to the advantages
of high drug loading, platform stability, and ease of scaling-up, nanocrystals have been widely used to
deliver poorly water-soluble drugs. Nanocrystals in the blood stream can be recognized and sequestered as
exogenous materials by mononuclear phagocytic system (MPS) cells, leading to passive accumulation in
MPS-rich organs, such as liver, spleen and lung. Particle size, morphology and surface modiﬁcation affect
the biodistribution of nanocrystals. Ligand conjugation and stimuli-responsive polymers can also be used
to target nanocrystals to speciﬁc pathogenic sites. In this review, the progress on injected nanocrystals for
targeted drug delivery is discussed following a brief introduction to nanocrystal preparation methods, i.e.,
top-down and bottom-up technologies.
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More than 40% of drug candidates in the drug development process
exhibit poor solubility, leading to poor and variable bioavailability1.
The non-speciﬁc distribution of most drugs throughout the body
results in side effects, further limiting their clinical use2. Targeting
strategies based on nanocarriers are important solutions for these
problems. Nanocarriers, i.e., liposomes, nanoparticles, micelles and
nanoemulsions, have been widely used to selectively deliver poorly
soluble drugs to pathological tissues, organs or cells3. However, the
intrinsic drawbacks, such as platform instability, limited drug
loading, high manufacturing cost, scale-up difﬁculties, and quality
control difﬁculties, contribute to the limited acceptance of these
nanocarriers in clinic4. Only a couple of nanocarrier-based prepara-
tions are successfully marketed, e.g., Doxils, DaunoXomes and
Abraxanes.
Development of nanocrystals emerged amid various shortcom-
ings of existing delivery techniques for targeted therapy. Nano-
crystals are drug crystals with particle size ranging from dozens to
a few hundreds of nanometers, while in some cases, pure drug
crystals may be physically stabilized by surfactants and/or poly-
mers5–7. Absence of any carrier chemicals offer a theoretic drug
loading up to 100%, typically 50%–90% (w/w)8, leading to
satisfactory therapeutic concentrations at low dose9. Toxic side-
effects resulting from the encapsulating/solubilizing excipients
also may be eliminated. Most importantly, physical instability
issues inherent with other nanocarriers are largely circumvented by
the nanocrystal formulation10–12. In addition, both top-down and
bottom-up technologies have been well developed to prepare
nanocrystals with desired particle size and size distribution, while
the ease of scaling-up for nanocrystals can be proved by a dozen of
commercial products13.
Although invented for oral delivery to improve bioavailability
of poorly soluble drugs, nanocrystals can be intravenously injected
due to the nanoscale dimension. Due to lack of local mixing and
initially insufﬁcient volume of distribution, nanocrystals are not
expected to dissolve rapidly in the blood upon i.v. administration,
leading to improved biodistribution as compared to orally admini-
strated nanocrystals4. The injected nanocrystals are recognized as
exogenous materials and sequestered by mononuclear phagocytic
system (MPS) cells. Consequently, nanocrystals in the blood
stream are passively targeted to organs in which MPS cells are
abundant, such as liver and spleen14,15. It has been reported that
the sequestering and transportation of exogenous particles by MPS
cells is very fast and efﬁcient. Up to 90% of the injected dose is
transported to liver and about 5% to spleen within 5 min after
injection9. The phagocytotic uptake by MPS cells is triggered by
the adsorbance of opsonins from the blood onto the nanocrystal
surface. Surface modiﬁcation with hydrophilic polymers, such as
polyethylene glycol (PEG) and poloxamer, can reduce opsoniza-
tion and thus prolongs the circulating time of nanocrystals in
blood, facilitating tumor accumulation through enhanced perme-
ability and retention (EPR) effects9,16. The targeting efﬁciency of
nanocrystals may be further improved using ligand modiﬁcation17.
Besides tumor sites, targeting to other pathogenic sites like
inﬂammation can be achieved by adopting stimuli-response
strategies16.
In this review, preparative methods for nanocrystals will be
brieﬂy introduced, followed by a detailed review on the progress
of targeted drug delivery by nanocrystals. Polymer encapsulation
to increase nanocrystal stability and immobilize ligands on the
surface of nanocrystals will also be included.2. Preparation of nanocrystals
2.1. Top-down techniques
High-energy mechanical forces are involved in the top-down
approaches, which can be provided either by media milling (MM)
(NanoCrystalss) or high-pressure homogenization (HPH)
(IDD-Ps, DissoCubess and Nanopures) to comminute large
crystals14,15. The biggest advantage in top-down process is that it
is a universal technique to prepare crystalline nanoparticles6 and is
ﬂexible in production scale18. Thus, the process has been widely
adopted to prepare commercial nanocrystals. Almost all commer-
cial products were produced by NanoCrystalss except for
Triglides by IDD-Ps. The disadvantage of this technology
includes high energy and time consumption as well as contamina-
tion from the grinding media. For example, even with high
pressure up to 1700 bar, 50–100 cycles of homogenization are
still required to achieve the desired particle size and size
distribution5,11; similarly, the milling time varies from hours to
days, depending on the properties of the drug, the milling media,
and the extent of particle size reduction19,20. Since contamination
from the grinding media leads to unexpected side-effects, the top-
down process may not be the optimal alternative to prepare
nanocrystals for i.v. injection.
2.1.1. Media milling (NanoCrystalss)
A milling chamber, motor, recirculating chamber, coolant and
milling media are the major components of the media mill (Fig. 1).
In the process, the milling chamber is fed with a crude slurry
containing drug, water and stabilizers, and agitated by the motor.
Generally, the slurry occupies 2%–30% (w/v) volume of
the milling chamber, while the milling media occupy 10%–50%
(w/v) of the slurry. During agitation, the milling media roll over
inside the chamber, generating high energy forces by shearing and
impacting with drugs to reduce the particle size. The operation can
be performed either in batch (discontinuous mode) or recirculation
mode (continuous mode), depending on the scale. Recirculation is
advantageous to reduce milling time and decrease particle size.
The milling media can be retained in the chamber by media
separators if recirculation mode is performed. Thermogenesis is
severe due to the high energy generated during milling and long-
term operation, leading to stability concerns. Therefore, the cool-
ant is a necessity to control the temperature during the milling
process.
2.1.2. High pressure homogenization (IDD-Ps, DissoCubess
and Nanopures)
During the process of HPH, drug suspensions are introduced into a
high pressure homogenizer and forced to pass through a very
narrow homogenization pathway in a sudden burst under high
pressure (Fig. 2). Fracture of drug particles is achieved by
cavitation, high-shear forces and collisions among particles. The
process is generally composed of three steps: (1) dispersion of
crude drug powders in pure solution or in solution containing
stabilizer, (2) reduction of particle size by high-speed shearing or
homogenization under low pressures, (3) high pressure homo-
genization to achieve the desirable particle size and size distribu-
tion. Based on the instruments and solution used, HPH can be
further divided into three patented technologies: microﬂuidizer for
IDD-Ps technology, piston gap homogenizer for DissoCubess
(water) and Nanopures (non-aqueous media).
Figure 1 Illustration of the media milling process. A crude slurry consisting of drug, water and stabilizer is fed into the milling chamber, which is
agitated by a motor. The particle size of drug powders is reduced by shearing forces and impaction between milling media and drug. Recirculation
can increase the milling efﬁciency, while the coolant can control the temperature of the materials. The milling time required to generate
nanocrystals depends on the properties of the drugs, the milling media and the extent of particle size reduction, varying from hours to days.
Figure 2 Illustration of the high pressure homogenization process. Pretreated drug suspensions are forced through a tiny gap or specially
designed homogenization chamber (Z- or Y- type) under high pressure, typically 1500–2000 bar. During this process, cavitation generated by high
streaming velocity, together with high shear forces and collisions among particles, comminute big drug crystals to nanocrystals. A high number of
passes, such as 50–100 passes, is still required even under 1700 bar to obtain the desirable particle size and size distribution.
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The bottom-up process grows nanocrystals from solution, which
includes two crucial steps: nucleation and consequent crystal
growth. In comparison, nucleation is especially important to
achieve small and uniform nanocrystals. Higher nucleation rate
increases the number of nuclei formed from the supersaturated
solution, leading to decreased supersaturation. Less growth of each
nucleus in the end can be anticipated as a consequence21. Also, if a
large number of nuclei are produced concurrently in the nucleation
stage, a narrow particle size distribution is obtained21. Therefore, it
is essential to promote rapid and homogeneous nucleation in the
bottom-up process.
Nucleation can be triggered by either mixing with antisolvent or
removal of solvent21,22. The mixing of drug solution and anti-
solvent is generally achieved with conventional mixing equipment,
i.e. magnetic stirring and agitator blade23. In order to promote thenucleation, sonication can be introduced to provide cavitation
effects (Fig. 3)24,25. This method is called sonoprecipitation. Some
highly efﬁcient mixing equipments have also been used to prepare
nanocrystals, including conﬁned impinging jet reactor26–30, multi-
ple inlet vortex mixer31 and static mixer32. With these instruments,
intense micro-mixing between the two ﬂuids is fulﬁlled in the
order of milliseconds33,34. A homogeneous solution with high
supersaturation may be achieved even before the onset of
nucleation, favoring small nanocrystals with narrow size distribu-
tion. Spray-drying and freeze-drying are common ways to remove
solvent. Recently, spray-freezing into liquid35–38 and controlled
crystallization during freeze-drying techniques39 also has been
developed to prepare nanocrystals by removal of solvent.
Supercritical ﬂuid (SCF) can be used to prepare nanocrystals by
taking advantage of the unique physical properties of SCF, with
combined diffusivity like gas and solubilization like liquid. In addition,
quick and easy removal of SCF without excessive drying can greatly
Figure 3 Schematic illustration of bottom-up techniques in which crystallization is triggered by solvent/anti-solvent mixing. Sonication can be
combined with a common mixing instrument such as magnetic stirring to promote nucleation (A). With highly efﬁcient mixing equipment,
including conﬁned impinging jet reactor (B), multiple inlet vortex mixer (C) and static mixer (D), intense micro-mixing may be achieved even
before the onset of nucleation, favoring small and homogeneous nanocrystals.
Injected nanocrystals for targeted drug delivery 109facilitate the precipitation of nanoparticles. Supercritical carbon dioxide
(SCO2) is the most favored SCF due to the mild critical point (31 1C
and 73.8 bar) and low environmental impact. Depending on the
solubility of a compound in SCO2, nanocrystal preparation can be
achieved by rapid expansion of SCO2 from drug solution
40, or by
precipitation using SCO2 as the antisolvent
41–43.3. Targeted delivery by nanocrystals
3.1. In vivo distribution of nanocrystals
Due to being sequestered and transported by MPS cells, i.v. injected
nanocrystals distribute more in MPS cell-abundant organs, such as
liver, spleen and lung, than the solution counterpart4,14,15. Nevirapine
nanocrystals are more easily taken up in vitro by macrophages than the
solution formulation, showing 2.76-fold higher nevirapine concentra-
tion in macrophages at the end of a two-hour culture. Therefore,
gamma scintigraphy conﬁrmed that nevirapine nanocrystals accumu-
lated more in MPS-rich organs including spleen, liver and thymus, as
well as exhibited prolonged residence at the target sites in comparison
to pure drug solution44. Similarly, the relative targeting efﬁcacy (re
c)
values of liver, lung and spleen for amoitone B nanocrystals (275 nm)
are 3.32, 2.50 and 1.42, respectively, compared to the solution
(Table 144–52). The nanocrystals remained in liver and lung for a
longer time, beneﬁting therapy in liver and lung45,46. Indeed, hydro-
xycamptothecin nanocrystals (168 nm) were highly accumulated in
liver, spleen and lung47. The area under curve (AUC) of hydroxy-
camptothecin nanocrystals in liver, spleen and lung respectively are
410-, 46- and 40- fold higher than that obtained with a solution
formulation (Table 1).
Particle size may play a signiﬁcant role in the biodistribution of
nanocrystals. Oridonin nanocrystals were prepared by HPH, with mean
particle size of 103 nm and 897 nm achieved by adjusting the
homogenization pressure. The more ﬁnely ground sample showed
similar biodistribution to the solution, as indicated by the re
c values in
all tested organs around 1 (Table 1). However, the cruder preparation
showed different biodistribution characteristics. Highest accumulation
was observed in liver with re
c values of 8.82, followed by spleen of 7.79
and lung of 3.23 (Table 1)48. Similar distribution characteristics were
observed for i.v. injected riccardin D nanocrystals with differentparticle sizes49. As described by the Ostwald-Freundlich equation,
nanocrystals exhibit nonlinear increase in kinetic solubility upon
particle size reduction53. It is thus hypothesized that the smaller
nanocrystals dissolve relatively quickly in blood, minimizing phago-
cytosis by the MPS cells and presenting similar in vivo behavior to the
solution17. On the contrary, larger particles are more likely to be
phagocytosed by the MPS, resulting in greater distribution to liver,
spleen and lung48,49. The size effects on biodistribution are still
controversial. Asulacrine nanocrystals, 133 nm, were prepared by
HPH. Although having enhanced dissolution and saturation solubility,
the nanocrystals still showed a signiﬁcantly greater accumulation in
liver, lung and kidney with altered pharmacokinetics, as compared to
the solution54. AZ68 amorphous nanosuspensions, 100–150 nm,
showed enhanced oral bioavailability over the crystalline nanocrystals,
300–400 nm, due to enhanced solubility and dissolution rate. However,
no signiﬁcant difference was found in the pharmacokinetic parameters
when comparisons were made between the formulations after i.v.
administration55. Nanocrystals are usually adopted by insoluble drugs.
Given the insoluble properties (usuallyo0.1 mg/mL), especially for
anticancer drugs56, combined with high i.v. dose, injected nanocrystals
are not expected to dissolve rapidly due to lack of local mixing and
insufﬁcient initial volume for distribution4.
Particle morphology also inﬂuences the biodistribution of nanocrys-
tals. Spherical and rod-like 10-hydroxycamptothecin nanocrystals
(500 nm) were prepared with similar hydrodynamic sizes and surface
charges57. The rod-like nanocrystals showed signiﬁcantly higher uptake
by KB cells than the spherical ones. Therefore a shape-dependent
cytotoxicity was observed. In addition, in vivo studies showed
obviously superior antitumor efﬁcacy was achieved by the rod-like
nanocrystals over the spherical one and free drug solution, and no
statistically signiﬁcant weight loss was observed. Similarly, the needle-
shaped camptothecin nanocrystals (250 nm) accumulated more in the
lung, because the high aspect ratio may hinder the escape from local
entrapment58.
Surface modiﬁcation of nanocrystals may change their biodistribu-
tion behaviors. Serum albumin, PEG and dextran was physically
adsorbed on the surface of nevirapine nanocrystals by simply incubat-
ing the bare nanocrystals in the modiﬁer solution50. Surface modiﬁca-
tion with PEG reduced the uptake of nanocrystals by primary
macrophages. On the contrary, surface modiﬁcation with serum
albumin and dextran showed 1.39 and 1.22 fold higher cellular drug
Table 1 Biodistribution properties of i.v. injected nanocrystals and factors affecting biodistribution.
Drug Stabilizer Size
(nm)
Animal model Reference
preparation
Biodistribution (re
ca) Ref.
Blood Heart Liver Spleen Lung Kidney Tumor Thymus
Am-B PC/F68 275 Mice Solution 2.07 0.77 3.32 1.42 2.50 0.82 45,46
HCPT None 168 H22 bearing
mice
Solution 8.78 7.01 410.49 46.05 40.63 42.03 5.72 47
Effects of particle size on the biodistribution
ORI F68/PC 103 Mice Solution 1.05 1.09 0.97 0.88 1.09 1.05 48
897 2.44 1.25 8.82 7.79 3.23 1.59
RD F68/PVP/
HPMC
184 Mice Solution 0.40 0.89 1.33 2.65 1.08 1.43 49
815 0.93 1.29 2.34 3.71 4.98 1.48
Effects of surface modiﬁcation on the biodistribution
NVP None 458 Rats Solution 1.75 1.16 1.77 2.56 0.62 0.75 4.22 44,50
Serum
albumin
495 Solution 1.02 0.60 2.60 3.74 4.75 0.57 6.21
Bare
nanocrystals
0.58 0.52 1.47 1.46 7.66 0.76 1.47
PEG 520 Solution 1.86 1.36 2.65 2.82 2.19 0.85 3.46
Bare
nanocrystals
1.06 1.17 1.50 1.10 3.53 1.13 0.82
Dextran 520 Solution 1.14 0.86 2.51 2.80 2.27 0.54 4.36
Bare
nanocrystals
0.65 0.74 1.42 1.09 3.66 0.72 1.03
Effects of ligand conjugation on biodistribution
PIK-75 PC/F68 182 SKOV-3
bearing Mice
Solution 0.77 13.76 0.91 0.72 4.69 51
PC/FA-F68 161 0.80 15.90 0.82 0.38 8.90
DTX PC/DSPE-
PEG
204 B16 bearing
mice
Solution 0.97 17.86 9.80 3.23 0.93 5.22 52
PC/DSPE-
PEG-FA
221 0.96 17.14 9.97 3.37 0.95 5.92
Am-B, amoitone B; DTX, docetaxel; F68, Pluronic F68; FA, folic acid; HCPT, hydroxycamptothecin; NVP, nevirapine; ORI, oridonin; PC,
phosphatidylcholine; RD, riccardin D.
aRelative efﬁciency, calculated by the AUC value of the tested preparation divided by that of the reference preparation.
Yi Lu et al.110concentration at the end of 2 h than that of bare nanocrystals. As a
consequence, surface modiﬁcation with serum albumin and dextran
decreased the accumulation of bare nanocrystals in blood, while
increased accumulation in liver, spleen and lung, both due to fast
uptake by macrophages. Furthermore, the nevirapine nanocrystals were
able to cross blood-brain barrier in less than 30 min and maintained
adequate levels up to 24 h after modiﬁcation with serum albumin.
None of the other nanocrystals formulations, modiﬁed or not, showed
signiﬁcant levels in brain. Polycations, including IgG, protamine and
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), were once used
to coat the bare paclitaxel (PTX) nanocrystals by physical adsorption59.
DOTAP-coated nanocrystals (DOTAP-NCs) showed faster in vitro
macrophage uptake than other coated and bare nanocrystals, especially
by immature CD14þCD16 cells relative to mature CD14þCD16þ
cells. The cellular uptake rate was in accordance with the sequence of
positive charge. On the contrary, the IgG-coated nanocrystals were
more preferentially taken up by the CD14þCD16þ monocyte subset
class due to binding of IgG to FcγR-III receptor on CD16þ.
Additionally, DOTAP-coated nanocrystals were taken up more readily
by peritoneal macrophages and OVCAR-3 cancer cells than were
uncoated nanocrystals. Subsequent experiments in vivo suggested that
DOTAP-coated nanocrystals could be trafﬁcked preferentially to the
tumor site by macrophages59.
Direct evidence showing in vivo macrophage uptake and
transportation of nanocrystals is still missing. Instead, there are
numerous speculations from the altered pharmacokinetics, involvinglower Cmax and longer t1/2, due to slow release from the deposition
of macrophages. A transmission electron micrograph of spleen from
a rat that received i.v. injection of itraconazole nanocrystals once
showed crystalline materials in the macrophages60. Although the
crystalline materials were attributed to itraconazole nanocrystals,
they may be resulted from the recrystallization of itraconazole
molecules during sample preparation, because ethanol was used for
dehydration before resin section. Cryo-TEM may be a good
alternative to study the in vivo fate of nanocrystals.
3.2. Ligand targeted delivery
To facilitate targeting to cancer cells, the strategy of using various
ligands that bind speciﬁcally to a receptor expressed by malignant cells
is attractive. Attaching ligands to the surface of nanocrystals can thus
deliver the drug speciﬁcally to the cancer cell via receptor-mediated
endocytosis with minimal accumulation at nonspeciﬁc sites. Note that
modiﬁcation with “stealth” molecules like PEG and poloxamer to
avoid quick clearance by macrophages is still essential.
Folate-based targeting systems present an effective means of
selectively delivering therapeutic agents to tumors, because the
folate receptor is overexpressed on many human cancer cells, folate
has low immunogenicity, its ease of modiﬁcation, good tissue
penetration and rapid clearance from receptor-negative tissues.
Folate-modiﬁed PIK-75 (a phosphatidylinositol 3-kinase inhibitor)
nanocrystals were prepared by HPH with Pluronic F68-folate
Injected nanocrystals for targeted drug delivery 111conjugate as the stabilizer51. Folate modiﬁcation was achieved
through physical adsorption of Pluronic F68 on the surface of the
nanocrystals. The folate-modiﬁed nanocrystals showed a 1.8-fold
and 1.4-fold higher PIK-75 concentration in SKOV-3 cells at 1 h
and 6 h of incubation respectively compared to nanocrystals without
folate modiﬁcation. Both nanocrystals showed similar distribution in
liver, kidney, spleen and lung. However, the folate-modiﬁed
nanocrystals increased their AUC by 1.90-fold at the tumor site
compared to non-modiﬁed nanocrystals (Table 1).
Ligand modiﬁcation will not always increase the tumor distribution
of nanocrystals. Folate conjugated with distearoylphosphatidyl
ethanolamine-PEG2000 (DSPE-PEG2000-FA) was used to coat doc-
etaxel nanocrystals52. The folate-modiﬁed nanocrystals showed
increased cellular toxicity as compared to nonfolate-modiﬁed nano-
crystals in folate receptor positive cell lines (B16 cells), and was
attributed to folate-induced internalization by the target cells. In
contrast, both nanocrystals showed similar in vivo distribution in B16
tumor-bearing mice including the tumor sites (Table 1). Instead of
being chemically anchored, the ligands are reversibly adsorbed onto the
surface of nanoparticles through stabilizers. Although equilibrium can
be reached between adsorbance and desorption in solution, stabilizers
can be detached from nanocrystals upon mild heating or dilution61,
inevitably resulting in loss of the stabilizing agent as well as any
appended ligands by in vivo dilution. Furthermore, the binding between
ligands and receptors on the surfaces of the target sites may be
preferential over the absorbance between stabilizers and nanocrystals,
leading to the binding of ligands alone to the receptors62.
3.3. Stimuli-responsive drug delivery
Generally, stabilizer adsorbed onto the surface of nanocrystals can
prevent aggregation by providing steric and/or electronic repul-
sions. An optimal surfactant thus should have high afﬁnity to the
surface of nanocrystals. But in some cases, shedding of the
stabilizer in response to a local endogenous stimulus may in fact
be beneﬁcial. For instance, shedding of D-α-tocopheryl polyethy-
lene glycol 1000 succinate (TPGS) from the paclitaxel nanocrys-
tals improved the toxicity to multidrug resistant cells by inhibiting
P-glycoprotein (P-gp)63. Polymers that undergo physiochemical
changes in response to environmental stimuli such as temperature,
pH, magnetic ﬁeld or enzymes have been widely used for drug
delivery. Adoption of these stimuli-responsive polymers as stabi-
lizers may allow nanocrystals to accumulate at sites of disease.
Reactive oxygen species (ROS) are strongly associated with and
limited to inﬂammation and cancer sites, stimulating investigations of
ROS-sensitive drug delivery systems64–66. A library of 10 redox-
responsive amphiphilic block copolymers was prepared by post-
polymerization modiﬁcation using the thiol-yne reaction8. The hydro-
phobic thiol agents grafted to the polymer endowed these copolymers
with good stabilizing effects to prepare paclitaxel nanocrystals with
mean diameters of around 200 nm. Oxidation of the thioether side
chain to a sulfoxide or sulfone signiﬁcantly alters the polarity of the
hydrophobic block, leading to desorption of the copolymers from the
surface of the nanocrystals. Compared to other ROS sensitive systems,
the prepared copolymers are more sensitive to H2O2 (as low as
100 μmol/L) and respond relatively quickly (within 2 h). The redox-
responsive copolymers may pave the way for the design of ROS-
sensitive drug delivery systems by location-speciﬁc shedding of
stabilizers, which can be used for imaging or improving cellular uptake.
The pH at pathological sites, involving inﬂammation, infection or
tumors, is lower than that of the normal tissues, which can be exploited
to achieve site-speciﬁc activation of many pharmaceutical andtherapeutic agents67. Calcium carbonate (CaCO3) nanocrystals were
synthesized in oil-in-water microemulsions using a high pressure
homogenizer to deliver doxorubicin (CaCO3/Dox nanocrystals)
68.
CaCO3/Dox nanocrystals showed a pH-dependent Dox release pattern,
i.e. slow release at normal physiological pH value (7.4) while a fast
release at acidic pH value (4.8) simulating tumor microenvironment.
The cellular experiments further indicated that CaCO3/Dox nanocrys-
tals are promising materials in the delivery of anticancer drugs.4. Encapsulation of nanocrystals
As discussed above, stabilizers are generally reversibly adsorbed onto
the surfaces of drug nanocrystals, being easily shed from the
nanocrystals by dilution or heating. The desorption of stabilizers may
cause stability concerns or even affect the in vivo performance of
nanocrystals. An improvement for this issue is to encapsulate
nanocrystals in cages.
The layer-by-layer (LbL) assemble technique is an effective way to
stabilize particles, based on the iterative adsorption of oppositely
charged polymers on a surface23. Compared with the one-layer
physisorption of stabilizers, the iterative coating may provide a ﬁrm
shell to stabilize nanocrystals. Tamoxifen (TMF) and paclitaxel (PTX)
nanocrystals (between 100 nm and 200 nm) can be stabilized by the
LbL assembly technique with positively charged poly(allylamine
hydrochloride) (PAH), poly (dimethyldiallylamide ammonium chlor-
ide) (PDDA), and negatively charged sodium poly (styrene sulfonate)
(PSS), respectively69. LbL coating did not signiﬁcantly alter the particle
sizes and morphologies of nanocrystals, while drug release can be
easily controlled by changing the coating thickness or composition.
Furthermore, with polyamino-containing PAH as the outer layer, the
speciﬁc targeting ligands such as mAb 2C5 can be conjugated to
LbL-stabilized PTX nanocrystals, leading to increased cytotoxicity to
MCF-7 and BT-20 cells.
Cross-linking of stabilizers adsorbed onto the surface of nanocrystals
is another option to avoid shedding of stabilizers. Chitosan was used as
a stabilizer to prepare PTX nanocrystals by media milling, followed by
immobilization onto the surface of the nanocrystals through cross-
linking with tripolyphosphate62. Furthermore, folate was introduced to
the surface of the cross-linked chitosan/drug nanocrystals by conjuga-
tion through N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydro-
chloride (EDC). The cross-linked chitosan, acting as a diffusion barrier,
decreased the release of PTX, while conjugation further decreased the
release due to the reinforced hydrophobicity by folate. Cross-linking by
click chemistry can also be used to encapsulate nanocrystals.
Amphiphilic copolymer was synthesized by ring-opening copolymer-
ization with mPEG as a hydrophilic segment to provide steric
stabilizing effects and alkynyl containing poly(δ-valerolactone) as
hydrophobic segment to adsorb on to PTX nanocrystals70. The
adsorbed copolymer can be crosslinked by diazido-containing mole-
cules through click chemistry around nanocrystals, forming a non-
sheddable polymeric “nanocage”. The nanocages were found to act as
sterically stabilizing barriers to prevent aggregation and provided a
means for enhanced retention of targeting agents on nanocrystals.
Although all of the abovementioned cross-linked nanocrystals show
potential in improved stability and targetability, biodistribution and
cellular uptake studies have not been reported.5. Summary and future perspective
Compared with traditional nanocarriers, the advantages of nano-
crystals in physical stability, high drug loading and relative ease of
Yi Lu et al.112production bring attractive alternatives for delivery of poorly
soluble drugs. Both top-down and bottom-up techniques have
been developed for preparing nanocrystals. The bottom-up tech-
niques may be more suitable to prepare nanocrystals for i.v.
injection than the top-down techniques, considering the potential
contamination from milling media.
Due to quick ingestion by macrophages, the i.v. injected
nanocrystals can be passively delivered to MPS rich organs, such
as liver, spleen and lung. Particle size, morphology and surface
modiﬁcation may greatly inﬂuence the in vivo distribution of
nanocrystals. Although ligands facilitate targeting to cancer cells,
physically adsorbed ligands on the surface of nanocrystals may be
shed by dilution in vivo, losing the targeting function. However,
shedding of stabilizers in response to pH or oxygen may be
advantageous for targeted delivery to some speciﬁc pathogenic
sites like tumors or sites of inﬂammation. Furthermore, stabilizers
can be immobilized on the surface of nanocrystals by crosslinking,
which may enhance not only the stability of nanocrystals but also
retention of targeting agents.
However, both the in vitro cellular uptake and the in vivo fate of
nanocrystals have not been fully explored due to the limitation of
current detection technologies. The cellular uptake and in vivo
distribution of nanocrystals is generally detected by measuring the
amount of drug molecule present. It is difﬁcult to discriminate if
the results are due to the nanocrystals themselves or the dissolved
molecules. Hybrid nanocrystals, by physically integrating ﬂuo-
rescent dyes inside the crystal71–73, may be a good way to resolve
this issue. Only with complete understanding of the factors that
affect the performance of nanocrystals can an optimal formulation
be designed. In addition, with breakthroughs in the development of
novel methods and devices, we believe that i.v. injected nano-
crystals will occur in the near future.References
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